1-9 of 9
Sven-Erik Strand
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates

Darren R. Veach, Claire M. Storey, Katharina Lückerath, Katharina Braun, Christian von Bodman, Urpo Lamminmäki, Teja Kalidindi, Sven-Erik Strand, Joanna Strand, Mohamed Altai, Robert Damoiseaux, Pat Zanzonico, Nadia Benabdallah, Dmitry Pankov, Howard I. Scher, Peter Scardino, Steven M. Larson, Hans Lilja, Michael R. McDevitt, Daniel L.J. Thorek, David Ulmert
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (7): 2050–2060.
https://doi.org/10.1158/1078-0432.CCR-20-3614
Published: 01 April 2021
View article titled, PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
Open the PDF for PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates in another window
Includes: Supplementary data
Journal Articles

Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer

Daniel L.J. Thorek, Anson T. Ku, Nicholas Mitsiades, Darren Veach, Philip A. Watson, Dipti Metha, Sven-Erik Strand, Sai Kiran Sharma, Jason S. Lewis, Diane S. Abou, Hans G. Lilja, Steven M. Larson, Michael R. McDevitt, David Ulmert
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (2): 881–891.
https://doi.org/10.1158/1078-0432.CCR-18-1521
Published: 15 January 2019
View article titled, Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer
Open the PDF for Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Improved Tumor Targeting and Decreased Normal Tissue Accumulation through Extracorporeal Affinity Adsorption in a Two-Step Pretargeting Strategy

Linda Mårtensson, Rune Nilsson, Tomas Ohlsson, Hans-Olov Sjögren, Sven-Erik Strand, Jan Tennvall
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5572s–5576s.
https://doi.org/10.1158/1078-0432.CCR-07-0891
Published: 17 September 2007
View article titled, Improved Tumor Targeting and Decreased Normal Tissue Accumulation through Extracorporeal Affinity Adsorption in a Two-Step Pretargeting Strategy
Open the PDF for Improved Tumor Targeting and Decreased Normal Tissue Accumulation through Extracorporeal Affinity Adsorption in a Two-Step Pretargeting Strategy in another window
Journal Articles

Determining Maximal Tolerable Dose of the Monoclonal Antibody BR96 Labeled with 90Y or 177Lu in Rats: Establishment of a Syngeneic Tumor Model to Evaluate Means to Improve Radioimmunotherapy

Linda Mårtensson, Zhongmin Wang, Rune Nilsson, Tomas Ohlsson, Peter Senter, Hans-Olov Sjögren, Sven-Erik Strand, Jan Tennvall
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (19): 7104s–7108s.
https://doi.org/10.1158/1078-0432.CCR-1004-0004
Published: 03 October 2005
View article titled, Determining Maximal Tolerable Dose of the Monoclonal Antibody BR96 Labeled with <sup>90</sup>Y or <sup>177</sup>Lu in Rats: Establishment of a Syngeneic Tumor Model to Evaluate Means to Improve Radioimmunotherapy
Open the PDF for Determining Maximal Tolerable Dose of the Monoclonal Antibody BR96 Labeled with <sup>90</sup>Y or <sup>177</sup>Lu in Rats: Establishment of a Syngeneic Tumor Model to Evaluate Means to Improve Radioimmunotherapy in another window
Journal Articles

Blood Pharmacokinetics of Various Monoclonal Antibodies Labeled with a New Trifunctional Chelating Reagent for Simultaneous Conjugation with 1,4,7,10-Tetraazacyclododecane-N,N′,N″,N‴-Tetraacetic Acid and Biotin before Radiolabeling

Zhongmin Wang, Linda Mårtensson, Rune Nilsson, Pär-Ola Bendahl, Lars Lindgren, Tomas Ohlsson, Hans-Olov Sjögren, Sven-Erik Strand, Jan Tennvall
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (19): 7171s–7177s.
https://doi.org/10.1158/1078-0432.CCR-1004-0001
Published: 03 October 2005
View article titled, Blood Pharmacokinetics of Various Monoclonal Antibodies Labeled with a New Trifunctional Chelating Reagent for Simultaneous Conjugation with 1,4,7,10-Tetraazacyclododecane-<em>N,N</em>′,<em>N</em>″,<em>N</em>‴-Tetraacetic Acid and Biotin before Radiolabeling
Open the PDF for Blood Pharmacokinetics of Various Monoclonal Antibodies Labeled with a New Trifunctional Chelating Reagent for Simultaneous Conjugation with 1,4,7,10-Tetraazacyclododecane-<em>N,N</em>′,<em>N</em>″,<em>N</em>‴-Tetraacetic Acid and Biotin before Radiolabeling in another window
Journal Articles

Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab

Ola Lindén, Cecilia Hindorf, Eva Cavallin-Ståhl, William A. Wegener, David M. Goldenberg, Heather Horne, Tomas Ohlsson, Lars Stenberg, Sven-Erik Strand, Jan Tennvall
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (14): 5215–5222.
https://doi.org/10.1158/1078-0432.CCR-05-0172
Published: 20 July 2005
View article titled, Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, <sup>90</sup>Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab
Open the PDF for Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, <sup>90</sup>Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab in another window
Journal Articles

Change in Tumor-absorbed Dose due to Decrease in Mass during Fractionated Radioimmunotherapy in Lymphoma Patients

Cecilia Hindorf, Ola Lindén, Lars Stenberg, Jan Tennvall, Sven-Erik Strand
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (10): 4003s–4006s.
Published: 01 September 2003
View article titled, Change in Tumor-absorbed Dose due to Decrease in Mass during Fractionated Radioimmunotherapy in Lymphoma Patients
Open the PDF for Change in Tumor-absorbed Dose due to Decrease in Mass during Fractionated Radioimmunotherapy in Lymphoma Patients in another window
Journal Articles

Radioimmunotherapy Using 131I-labeled Anti-CD22 Monoclonal Antibody (LL2) in Patients with Previously Treated B-cell Lymphomas

Ola Lindén, Jan Tennvall, Eva Cavallin-Ståhl, Lennart Darte, Michael Garkavij, Karl-Johan Lindner, Michael Ljungberg, Tomas Ohlsson, Katarina Sjögreen, Karin Wingårdh, Sven-Erik Strand
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (10): 3287s–3291s.
Published: 01 October 1999
View article titled, Radioimmunotherapy Using <sup>131</sup>I-labeled Anti-CD22 Monoclonal Antibody (LL2) in Patients with Previously Treated B-cell Lymphomas
Open the PDF for Radioimmunotherapy Using <sup>131</sup>I-labeled Anti-CD22 Monoclonal Antibody (LL2) in Patients with Previously Treated B-cell Lymphomas in another window
Journal Articles

Comparison of 125I- and 111In-labeled Monoclonal Antibody BR96 for Tumor Targeting in Combination with Extracorporeal Immunoadsorption

Michael Garkavij, Jan Tennvall, Tomas Ohlsson, Lars Lindgren, Cecilia Hindorf, Hans-Olov Sjögren, Sven-Erik Strand
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (10): 3059s–3064s.
Published: 01 October 1999
View article titled, Comparison of <sup>125</sup>I- and <sup>111</sup>In-labeled Monoclonal Antibody BR96 for Tumor Targeting in Combination with Extracorporeal Immunoadsorption
Open the PDF for Comparison of <sup>125</sup>I- and <sup>111</sup>In-labeled Monoclonal Antibody BR96 for Tumor Targeting in Combination with Extracorporeal Immunoadsorption in another window